New Two-Pronged attack on Tough-to-Treat lung cancer
NCT ID NCT07339839
Summary
This study is testing a new combination of two drugs, glecirasib and ivonescimab, for people with advanced non-small cell lung cancer who have a specific genetic change called KRAS G12C and have not yet received treatment. The main goals are to find the safest and most effective dose of the drug combination and to see how well it shrinks tumors. The study will enroll about 42 participants across multiple centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.